Orgenesis Inc (ORGS)
$4.13
Performance
- $4.07$4.32$4.13
1.45%
Downside
Day's Volatility :5.84%
Upside
4.45%
- $2.50$10.80$4.13
39.47%
Downside
52 Weeks Volatility :76.85%
Upside
61.76%
Returns
| Period | Orgenesis Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -35.64% | 0.0% |
6 Months | -24.66% | 0.0% |
1 Year | -32.78% | 0.0% |
3 Years | -90.7% | -20.2% |
Highlights
Market Capitalization | 20.8M |
Book Value | - $3.3 |
Earnings Per Share (EPS) | -8.0 |
PEG Ratio | 0.0 |
Wall Street Target Price | 6.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1653.66% |
Return On Assets TTM | -30.08% |
Return On Equity TTM | -727.25% |
Revenue TTM | 662.0K |
Revenue Per Share TTM | 0.2 |
Quarterly Revenue Growth YOY | 117.7% |
Gross Profit TTM | 36.0M |
EBITDA | -19.1M |
Diluted Eps TTM | -8.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 45.28%
Technicals Summary
Sell
Neutral
Buy
Orgenesis Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Orgenesis Inc | -34.76% | -24.66% | -32.78% | -90.7% | -88.11% |
 Regeneron Pharmaceuticals, Inc. | -13.97% | 8.28% | 24.49% | 82.67% | 258.6% |
 Novo Nordisk A/s | -14.46% | -7.16% | 29.25% | 137.43% | 348.48% |
 Alnylam Pharmaceuticals, Inc. | 6.47% | 77.93% | 59.32% | 38.21% | 249.95% |
 Vertex Pharmaceuticals Incorporated | -5.23% | 12.26% | 28.5% | 155.67% | 163.05% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Orgenesis Inc | NA | NA | 0.0 | 0.0 | -7.27 | -0.3 | NA | -3.3 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Orgenesis Inc | Buy | $20.8M | -88.11% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 258.6% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 348.48% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 249.95% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.05% | 32.84 | -4.74% |
Insights on Orgenesis Inc
Increasing Revenue
Revenue is up for the last 3 quarters, -13.59M → 246.0K (in $), with an average increase of 4893.7% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, -34.39M → -8.90M (in $), with an average increase of 130.9% per quarter
Vs ALNY
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 59.3% return, outperforming this stock by 92.1%
Vs VRTX
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.2% return, outperforming this stock by 128.9%
Institutional Holdings
Vanguard Group Inc
1.94%Geode Capital Management, LLC
0.60%BlackRock Inc
0.17%State Street Corp
0.17%Northern Trust Corp
0.09%Bank Hapoalim BM
0.07%
Company Information
orgenesis inc (orgs) is a medical device company located in 21 sparrow cir, white plains, new york, united states.
Organization | Orgenesis Inc |
Employees | 146 |
CEO | Ms. Vered Caplan M.Sc. |
Industry | Health Technology |
Discover More
Eagle Pharmaceuticals Inc.
$4.13
-5.61%
Rumbleon Inc
$4.13
-5.61%
Olaplex Holdings, Inc.
$4.13
-5.61%
Bluebird Bio, Inc.
$4.13
-5.61%
Generation Income Properties Inc
$4.13
-5.61%
Ondas Holdings Inc
$4.13
-5.61%
Nuveen Credit Strat Incm
$4.13
-5.61%
Touchstone Climate Transition Etf
$4.13
-5.61%
Atlas Lithium Corp
$4.13
-5.61%